Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP)
inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and
tolerability of JTZ-951 when administered alone and one hour after the administration of
lapatinib.